Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using Quantitative Systems Pharmacology Model-Reference-Cited by-同舟云学术

Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using Quantitative Systems Pharmacology Model

Published:2024-06-20 Issue:7 Volume:84 Page:825-839
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Hey John A.^ORCID,Yu Jeremy Y.,Abushakra Susan,Schaefer Jean F.,Power Aidan,Kesslak Patrick,Tolar Martin

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40265-024-02068-7.pdf

Reference63 articles.

1. Tolar M, Abushakra S, Sabbagh M. The path forward in Alzheimer’s disease therapeutics: Reevaluating the amyloid cascade hypothesis. Alzheimers Dement. 2020;16(11):1553–60. https://doi.org/10.1016/j.jalz.2019.09.075.

2. Tolar M, Abushakra S, Hey JA, Porsteinsson A, Sabbagh M. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval. Alzheimers Res Ther. 2020;12(1):95. https://doi.org/10.1186/s13195-020-00663-w.

3. Tolar M, Hey J, Power A, Abushakra S. Neurotoxic soluble amyloid oligomers drive Alzheimer’s pathogenesis and represent a clinically validated target for slowing disease progression. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22126355.

4. Tolar M, Hey JA, Power A, Abushakra S. The single toxin origin of Alzheimer’s disease and other neurodegenerative disorders enables targeted approach to treatment and prevention. Int J Mol Sci. 2024. https://doi.org/10.3390/ijms25052727.

5. Hey JA, Yu JY, Versavel M, Abushakra S, Kocis P, Power A, et al. Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer’s disease. Clin Pharmacokinet. 2018;57(3):315–33. https://doi.org/10.1007/s40262-017-0608-3.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease;Drugs;2024-06-20